Singapore, Thursday, May 02, 2013 -- (Business Wire India) -- -- Jaslok, one of the most reputed hospitals in Mumbai, will adopt Napier's next generation mobile electronic health records platform that will empower over 1,100 users from the hospital to render faster, more efficient services to its patients.
Napier Healthcare Solutions, a leading healthcare software provider, is pleased to announce that Jaslok Hospital of Mumbai has selected the Napier HER m (pronounced EHR mobile) management suite of products for its end-to-end hospital management needs.
The fully mobile-enabled solution is Napier's next-generation platform that helps deliver the vision of a Digital Hospital. The Napier EHR m is an open-source based platform; when fully deployed in the course of the next few months, it will be used by over 1,100 users from the hospital.
Catalent Biologics Expands into ADCs Through Exclusive License with Redwood Bioscience SMARTagT Advanced Conjugation...
Somerset, New Jersey, United States, Thursday, April 11, 2013 -- (Business Wire India) --
Catalent Pharma Solutions has announced that it has acquired an exclusive license to market Redwood Bioscience's proprietary SMARTag T precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs). Redwood's novel, site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. Combined with Catalent's proprietary GPEx ® cell line expression system, its brand new state-of-the-art biomanufacturing Center of Excellence in Madison, Wisconsin and broad range of bioanalytical and fill-finish services, this deal marks a further expansion of Catalent's capabilities to help customers develop more and better biologic treatments.
Bangalore, Karnataka, India, Thursday, February 14, 2013 -- (Business Wire India) -- Biocon, Asia's premier biotechnology company today announced that it has entered into a definitive agreement with Mylan for an exclusive strategic collaboration for the global development and commercialization of generic versions of its three insulin analog products.